Results 151 to 160 of about 10,208 (189)

Protective Efficacy of Subunit Vaccine Expressing Rv0976c Against Tuberculosis. [PDF]

Vaccines (Basel)
Zhou Z, Chen D, Chen F, Xu W, Pan Z, Xiang Z, Gao X, Li Y, Zhong F, Liu J, Zhang L.   +10 more
europepmc   +1 more source

Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal. [PDF]

Heliyon
Hoseinpour R, Hasani A, Baradaran B, Abdolalizadeh J, Salehi R, Hasani A, Nabizadeh E, Yekani M, Hasani R, Kafil HS, Azizian K, Memar MY.   +11 more
europepmc   +1 more source

[Effects of a few -sympatholytics (propranolol, C.39'089-Ba, H56-28 and Ko 592) on serum cholinesterase of rats].

Japanese journal of pharmacology, 1971
openaire   +1 more source

Molecular Structure and Biosynthesis of Pyoverdines Produced by <i>Pseudomonas fulva</i>. [PDF]

Microorganisms
Ochiai E, Kawabe T, Shionyu M, Hasegawa M.   +3 more
europepmc   +1 more source

AI based predictive acceptability model for effective vaccine delivery in healthcare systems. [PDF]

Sci Rep
Qureshi MS, Qureshi MB, Iqrar U, Raza A, Ghadi YY, Innab N, Alajmi M, Qahmash A.   +7 more
europepmc   +1 more source

Crystal structure and Hirshfeld surface analysis of (1H-imidazole-κN³)[4-methyl-2-({[2-oxido-5-(2-phenyl-diazen-1-yl)phen-yl]methyl-idene}amino)penta-noate-κ³O,N,O']copper(II). [PDF]

Acta Crystallogr E Crystallogr Commun
Kaneda A, Suzuki S, Nakane D, Kashiwagi Y, Akitsu T.   +4 more
europepmc   +1 more source

Toll like-receptor agonist Pam3Cys modulates the immunogenicity of liposomes containing the tuberculosis vaccine candidate H56 [PDF]

Medical Microbiology and Immunology, 2020
AbstractA major roadblock in the development of novel vaccines is the formulation and delivery of the antigen. Liposomes composed of a dimethyldioctadecylammonium (DDA) backbone and the adjuvant trehalose-6-6-dibehenate (TDB, termed “cationic adjuvant formulation (CAF01)”, promote immunogenicity and protective efficacy of vaccines, most notably against
Gabriel Kristian Pedersen, Dennis Christensen, Steffen Stenger   +2 more
exaly   +3 more sources

Conservation in gene encoding Mycobacterium tuberculosis antigen Rv2660 and a high predicted population coverage of H56 multistage vaccine in South Africa

Infection, Genetics and Evolution, 2017
H56/AERAS-456+IC31 (H56), composed of two early secretion proteins, Ag85B and ESAT-6, and a latency associated protein, Rv2660, and the IC31 Intercell adjuvant, is a new fusion subunit vaccine candidate designed to induce immunity against both new infection and reactivation of latent tuberculosis infection.
Edison Ong, Yongqun He, Zhenhua Yang
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder

Vaccine, 2018
Liquid vaccine dosage forms have limited stability and require refrigeration during their manufacture, distribution and storage. In contrast, solid vaccine dosage forms, produced by for example spray drying, offer improved storage stability and reduced dependence on cold-chain facilities.
Aneesh Thakur, Pall Thor Ingvarsson, Signe Tandrup Schmidt   +2 more
exaly   +4 more sources

Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial

American Journal of Respiratory and Critical Care Medicine, 2019
Abstract Rationale Global tuberculosis (TB) control requires effective vaccines in TB-endemic countries, where most adults are infected with Mycobacterium tuberculosis (M.tb). Objectives We sought to define optimal ...
Sara Suliman, Angelique Kany Kany Luabeya, Hennie D Geldenhuys   +2 more
exaly   +3 more sources